A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs BGB 324 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
- 17 Nov 2017 According to a BerGenBio media release, first patient has been dosed.
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.
- 18 Aug 2017 According to a BerGenBio ASA media release, the company has completed IPO and the funds from the recent IPO will enable the company to complete the four ongoing phase II trials (NCT02488408, NCT02424617, NCT03184558, NCT03184571) including this trial with read-outs expected in the second half of 2018.